| Identification | Back Directory | [Name]
3'-O-MOE-5MeU-2'-phosphoramidite | [CAS]
256223-93-5 | [Synonyms]
3'-O-MOE-5MeU-2'-phosphoramidite
3’-O-MOE-5MeU-2’-phosphoramidite
5’-O-DMTr-3’-O-(2-methoxyethyl)-5-methyl uridine-2’-CED-phosphoramidite
Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-O-(2-methoxyethyl)-5-methyl-, 2'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI)
3-[({[(2R,3R,4R,5R)-5-[(bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)-2-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]oxy}(bis(propan-2-yl)amino)phosphanyl)oxy]propanenitrile | [Molecular Formula]
C43H55N4O10P | [MOL File]
256223-93-5.mol | [Molecular Weight]
818.89 |
| Hazard Information | Back Directory | [Uses]
3’-O-MOE-5MeU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
| Company Name: |
Pharmalego
|
| Tel: |
18321033991 |
| Website: |
https://cn.pharmalego.com/ |
|